Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building,
CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago,
UC = Conference Chicago at University Center
* = applied session ! = JSM meeting theme
251 * !
Mon, 8/1/2016,
2:00 PM -
3:50 PM
CC-W194b
Bayesian Modeling and Applications — Contributed Papers
Biopharmaceutical Section , International Society for Bayesian Analysis (ISBA) , Section on Bayesian Statistical Science
Chair(s): John Han, Johnson & Johnson
2:05 PM
A Phase 2a Bayesian Adaptive Dose-Ranging Trial Evaluating Hypertension Therapy
—
Richann Liu, Pfizer
2:20 PM
A Simple Bayesian Design to Identify Maximum Tolerated Dose Contour for Drug Combination Trials
—
Liangcai Zhang, Rice University ; Ying Yuan, MD Anderson Cancer Center
2:35 PM
Exploring Bayesian Go/No-Go Decision Criteria in Clinical Trials
—
Rodney Croos-Dabrera, Astellas Pharma ; Misun Lee, Astellas Pharma
2:50 PM
Use of Bayesian Methods in Dose-Escalation Studies
—
Mani Lakshminarayanan, Pfizer
3:05 PM
Precision Medicine: How Bayesian Empirical Subgroup Analysis Plays a Role
—
Judy X. Li, FDA ; Wei-Chen Chen, FDA/CBER ; John Scott, FDA
3:20 PM
Bayesian Statistical Models Assessing Disease Modification Drug Effects Using Doubly Randomized Delayed-Start and Matched Control Designs
—
Ibrahim Turkoz, Janssen R&D ; Marc Sobel, Temple University
3:35 PM
Bayesian Modeling of Phase II Dose-Ranging Clinical Trials
—
Shu-Yen Ho, PAREXEL
